# US 2010/0305087 A1 · Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305087 A1
- Document ID: US20100305087A1
- Status: Published application
- Kind: A1
- Application number: 12/809,576
- Filed: 2008-12-18
- Published: 2010-12-02
- Earliest claimed: 2007-12-21
- Assignees: Lek Pharmaceuticals D.D.
- Inventors: Rok Grahek; Aleksander Resman; Andrej Bastarda; Martin Crnugelj
- Web page: https://patentgrep.com/patent/US20100305087A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 9/143: {with inorganic compounds}
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A combination preparation comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable solid support, wherein said solid support is in a water-insoluble particulate form and comprises a material selected from silicic acid, aluminum hydroxide and titanium hydroxide is disclosed. The API is a compound having both, at least one hydrophobic structural moiety causing the API to have a low solubility in water or in an aqueous solution, and multiple hydrophilic groups arranged to form multiple intermolecular interactions to the solid support involving polar or ionic or hydrogen bonding. The hydrophilic groups of the API are independently equal or different and comprise at least one of the groups consisting of OH- and halogen-groups. The API is bound to the solid support by adsorption, and a major proportion of said API is in an amorphous state. Related pharmaceuticals and methods of preparation also are disclosed.

## Claims

### Claim 1

A combination preparation comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable solid support,
wherein said solid support is in a water-insoluble particulate form and comprises a material selected from the group consisting of silicic acid, aluminum hydroxide and titanium hydroxide,
wherein said API is a compound having both, at least one hydrophobic structural moiety causing the API to have a low solubility in water or an aqueous solution, and multiple hydrophilic groups arranged to form multiple intermolecular interactions to said solid support involving polar or ionic or hydrogen bonding,
wherein the hydrophilic groups of the API are independently equal or different and comprise at least one of the group consisting of OH- and halogen-groups;
wherein said API is bound to said solid support by adsorption, and wherein a major proportion of said API is in the amorphous state.

### Claim 2 (depends on 1)

The combination preparation according to claim 1, wherein the combination of said solid support and said API being adsorbed thereon displays a solubility in water or in an aqueous solution being increased by a factor of at least 1.5 relative to a referenced free form of the same API in the same aqueous solution.

### Claim 3 (depends on 1)

The combination preparation according to claim 1, wherein an interaction between said API and said solid support is such that a differential scanning calorimetry (DSC) thermogram of the combination preparation does not show any transition characteristic of the corresponding free form of said API alone.

### Claim 4 (depends on 1)

The combination preparation according to claim 1, wherein said API has at least 2 hydrophilic groups selected from OH- and halogen-groups.

### Claim 5 (depends on 1)

The combination preparation according to claim 1, wherein said API has both at least 1 OH-group, and at least 1 halogen-group.

### Claim 6 (depends on 1)

The combination preparation according to claim 1, wherein said API has further hydrophilic groups other than OH- and halogen-groups, the other groups being selected from the group consisting of chinoline-, beta-diketone-, amino-, amid-, carboxylic acid- and ester-groups.

### Claim 7 (depends on 1)

The combination preparation according to claim 1, wherein said API comprises the following structural configuration:
presence of at least 3 hydrophobic moieties, independently being same or different; and
each of at least 2 of said hydrophobic moieties are respectively bonded to at least one of said hydrophilic groups.

### Claim 8 (depends on 1)

The combination preparation according to claim 1, wherein said API is ezetimibe.

### Claim 9 (depends on 1)

The combination preparation according to claim 1, wherein said API is atovaquone.

### Claim 10 (depends on 1)

The combination preparation according to claim 1, wherein said solid support material comprises silicic acid.

### Claim 11 (depends on 1)

The combination preparation according to claim 1, wherein said solid support material comprises fumed silica or colloidal silica.

### Claim 12 (depends on 1)

The combination preparation according to claim 1, wherein said solid support is silicified microcrystalline cellulose.

### Claim 13 (depends on 1)

The combination preparation according to claim 1, wherein no substance other than said API is co-adsorbed onto said solid support.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A pharmaceutical preparation comprising a combination preparation of claim 1.

### Claim 16

A method for producing a combination preparation comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable solid support, the method comprising:
a) providing a suspended solution comprising:
a solid support which is in a hydrophilic particulate form and comprises a material selected from the group consisting of silicic acid, aluminum hydroxide and titanium hydroxide;
an API having both, at least one hydrophobic structural moiety causing the API to have low solubility in water or in an aqueous solution, and multiple hydrophilic groups arranged to form multiple intermolecular interactions to said solid support involving polar or ionic or hydrogen bonding, wherein the hydrophilic groups of the API are independently equal or different and comprise at least one of the groups consisting of OH- and halogen-groups; and
an organic solvent dissolving said API;
b) removing said organic solvent by evaporation; and
c) obtaining a combination preparation having said API bound to said solid support by adsorption, wherein a major proportion of said API is in the amorphous state.

### Claim 17 (depends on 16)

The process according to claim 16, wherein said step (b) is carried out by a slow evaporation of said organic solvent during a period of more than about 30 min.

### Claim 18 (depends on 16)

A combination preparation, which is obtained by the method of claim 16.

### Claim 19 (depends on 1)

The combination preparation according to claim 1, wherein said API has at least 3 hydrophilic groups selected from OH- and halogen-groups.

### Claim 20 (depends on 1)

The combination preparation according to claim 1, wherein said API has at least 4 hydrophilic groups selected from OH- and halogen-groups.

### Claim 21 (depends on 1)

The combination preparation according to claim 1, wherein said API has both at least 2 OH-groups, and at least 2 halogen-groups.
